Heart:超半数ICD置入者适宜初始S-ICD置入

2013-05-28 Heart CMT 高晓方 编译

  荷兰一项研究表明,超过半数的置入型心律转复除颤器(ICD)患者适合初始接受皮下ICD(S-ICD)治疗,并且数项基线临床特征有助于选择适宜患者。论文于5月23日在线发表于《心脏》(Heart)。   此项回顾性队列研究共纳入1345例接受单腔或双腔ICD治疗的患者,并进行了为期5年的随访。以随访期间未到达下述终点之一定义适合S-ICD治疗:心房和/或右室起搏适应证;无后续休克的成功抗心动过速

  荷兰一项研究表明,超过半数的置入型心律转复除颤器(ICD)患者适合初始接受皮下ICD(S-ICD)治疗,并且数项基线临床特征有助于选择适宜患者。论文于5月23日在线发表于《心脏》(Heart)。

  此项回顾性队列研究共纳入1345例接受单腔或双腔ICD治疗的患者,并进行了为期5年的随访。以随访期间未到达下述终点之一定义适合S-ICD治疗:心房和/或右室起搏适应证;无后续休克的成功抗心动过速性起搏;升级至CRT-D设备。

  结果显示,在中位3.4年随访其中,463例(34%)患者达到一项终点。5年之后,适合初始S-ICD治疗的ICD置入者的累积发生率为55.5%。不适合S-ICD治疗的显著预测因素包括二级预防、严重心衰和QRS持续时间延长。


Suitability for subcutaneous defibrillator implantation: results based on data from routine clinical practice

Objective 

To assess the proportion of current implantable cardioverter defibrillator (ICD) recipients who would be suitable for a subcutaneous lead ICD (S-ICD).

Design 

A retrospective cohort study.

Setting 

Tertiary care facility in the Netherlands.

Patients 

All patients who received a single- or dual-chamber ICD in the Leiden University Medical Center between 2002 and 2011. Patients with a pre-existent indication for cardiac pacing were excluded.

Main outcome measure 

Suitability for an S-ICD defined as not reaching one of the following endpoints during follow-up: (1) an atrial and/or right ventricular pacing indication, (2) successful antitachycardia pacing without a subsequent shock or (3) an upgrade to a CRT-D device.

Results 

During a median follow-up of 3.4 years (IQR 1.7–5.7 years), 463 patients (34% of the total population of 1345 patients) reached an endpoint. The cumulative incidence of ICD recipients suitable for an initial S-ICD implantation was 55.5% (95% CI 52.0% to 59.0%) after 5 years. Significant predictors for the unsuitability of an S-ICD were: secondary prevention, severe heart failure and prolonged QRS duration.

Conclusions 

After 5 years of follow-up, approximately 55% of the patients would have been suitable for an S-ICD implantation. Several baseline clinical characteristics were demonstrated to be useful in the selection of patients suitable for an S-ICD implantation.



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1860447, encodeId=bd98186044e5e, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Wed May 07 14:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355758, encodeId=3a441355e5816, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 30 07:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562156, encodeId=e306156215670, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu May 30 07:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=)]
    2014-05-07 yilong5287542
  2. [GetPortalCommentsPageByObjectIdResponse(id=1860447, encodeId=bd98186044e5e, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Wed May 07 14:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355758, encodeId=3a441355e5816, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 30 07:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562156, encodeId=e306156215670, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu May 30 07:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=)]
    2013-05-30 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1860447, encodeId=bd98186044e5e, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Wed May 07 14:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355758, encodeId=3a441355e5816, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 30 07:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562156, encodeId=e306156215670, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu May 30 07:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=)]
    2013-05-30 slcumt